La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Catalyst Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Catalyst Pharmaceuticals..

Catalyst Pharmaceuticals (NASDAQ:CPRX) Azioni, Catena delle Opzioni

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CPRX

VRNA

Scopriamo i 3 titoli sanitari che potrebbero affrontare un crollo a causa di indicatori di mercato e RSI elevati.

Scopri i 3 titoli sanitari che potrebbero crollare ad agosto

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals Inc

Stephens &amp; Co. analyst Sudan Loganathan initiates coverage on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Overweight rating and announces Price Target of $35.

Price Target

Initiation

Analyst Ratings

Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals with Overweight Rating, Announces Price Target of $35

Patrick J McEnany, Board Member at Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), reported an insider sell on November 13, according to a new SEC filing. 
What Happened: After conducting a thorough analysis, McEnany sold 492,000 shares of Catalyst Pharmaceuticals. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001369568/000116169724000445//Archives/edgar/data/1369568/000116169724000445/0001161697-24-000445-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total transaction value is $11,510,102.
Tracking the Thursday's morning session, Catalyst Pharmaceuticals shares are trading at $22.76, showing a down of 0.18%.
<h3>About Catalyst Pharmaceuticals</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Key Indicators: Catalyst Pharmaceuticals's Financial Health</h3>
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 25.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 85.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Catalyst Pharmaceuticals's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.37.
</li>
</ul>
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 19.32 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 6.03 is lower than the industry average, implying a discounted valuation for Catalyst Pharmaceuticals's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 10.79 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001369568">Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock

Truist Securities analyst Joon Lee maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $30 to $36.

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $36

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $30 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $30 Price Target

<ul>
<li>Expect total revenues for the full year 2024 to be between $475 million and $485 million, which includes the $2.1 million milestone payment received from DyDo that is included in License and other revenue. &nbsp;</li>
<li>Revising full-year 2024 net product revenue guidance for FIRDAPSE to be between $300 million and $310 million;&nbsp;reaffirming FYCOMPA net product revenue guidance to be between $130 million and $135 million; and increasing AGAMREE net product revenue guidance to be between $40 million and $45 million, respectively. &nbsp;</li>
<li>Revising full year research and development ("R&amp;D") expense guidance to less than $15 million due to delays in the timing of certain R&amp;D related initiatives.</li>
</ul>

Guidance

Catalyst Pharmaceuticals Sees FY24 Revenue $475M-$485M Vs $473.67  Est.

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.30 by 90 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $126.42 million which beat the analyst consensus estimate of $123.42 million by 2.43 percent. This is a 23.11 percent increase over sales of $102.69 million the same period last year.

Earnings

Earnings Beats

Catalyst Pharmaceuticals Q3 Adj $0.57 Beats $0.30 Estimate, Sales $126.42M Beat $123.42M Estimate

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Catalyst Pharmaceuticals to report an earnings per share (EPS) of $0.30.
Anticipation surrounds Catalyst Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.30, leading to a 12.75% increase in the share price on the subsequent day.
Here's a look at Catalyst Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.26</td>
<td>0.17</td>
<td>0.26</td>
<td>0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.56</td>
<td>0.38</td>
<td>0.53</td>
<td>0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>13.0%</td>
<td>6.0%</td>
<td>10.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730833333_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Catalyst Pharmaceuticals were trading at $21.75 as of November 04. Over the last 52-week period, shares are up 74.24%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Observations about Catalyst Pharmaceuticals</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals has received a total of 3 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $30.33, the consensus suggests a potential 39.45% upside.
<h3>Comparing Ratings with Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Geron, Alnylam Pharmaceuticals and Twist Bioscience, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Buy trajectory for Geron, with an average 1-year price target of $6.75, indicating a potential 68.97% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Alnylam Pharmaceuticals, with an average 1-year price target of $53.5, indicating a potential 145.98% upside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Twist Bioscience, with an average 1-year price target of $52.0, indicating a potential 139.08% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Geron, Alnylam Pharmaceuticals and Twist Bioscience, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalyst Pharmaceuticals</td>
<td>Buy</td>
<td>23.23%</td>
<td>$107.31M</td>
<td>6.97%</td>
</tr>
<tr>
<td>Geron</td>
<td>Buy</td>
<td>2941.38%</td>
<td>$865K</td>
<td>-20.68%</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>Outperform</td>
<td>21.15%</td>
<td>$8.18M</td>
<td>82.89%</td>
</tr>
<tr>
<td>Twist Bioscience</td>
<td>Neutral</td>
<td>27.81%</td>
<td>$35.27M</td>
<td>-16.28%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Catalyst Pharmaceuticals ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>Unveiling the Story Behind Catalyst Pharmaceuticals</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>A Deep Dive into Catalyst Pharmaceuticals's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Catalyst Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 23.23%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Catalyst Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 33.24%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Catalyst Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Catalyst Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 6.03%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Catalyst Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/CPRX/earnings">To track all earnings releases for Catalyst Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Catalyst Pharmaceuticals's Future Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz.
The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eds#NASDAQ">EDS</a>) in patients aged seven years and older with narcolepsy.
The company&#39;s shares rose 5.1% on the news.&nbsp;
The stock fell 1.4% year to date compared with the <a href="https://www.zacks.com/stocks/industry-rank/industry/medical-biomedical-and-genetics-105">industry</a>&#39;s 0.7% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/97/81744.jpg?v=1324361988" style="height:245px; width:624px" /> 
Image Source: Zacks Investment Research
<h3>Label Expansion Of AVDL&#39;s Lumryz</h3>
Lumryz is a once-at-bedtime formulation extended-release sodium oxybate. It was first approved by the FDA on May 1, 2023, for the treatment of cataplexy or EDS in adult patients with narcolepsy.
Along with the approval, the FDA also granted seven years of orphan drug exclusivity to Lumryz for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of Lumryz relative to currently available oxybate treatments.
Narcolepsy is a chronic neurological condition, wherein the brain&#39;s ability to regulate the sleep-wake cycle is impaired.
The latest FDA approval expands the drug&#39;s indication for younger narcolepsy patients.&nbsp; The drug was also granted orphan drug exclusivity in pediatric narcolepsy patients aged seven years and older through Oct. 16, 2031.
Pediatric patients (seven years and older) living with narcolepsy will now have the same opportunity that adult patients with narcolepsy have &mdash; to choose a once-nightly treatment option that does not disrupt sleep for a middle-of-the-night dose.
<h3>Lumryz Uptake Boosts AVDL</h3>
Avadel generated $41.5 million of net product revenues from the sales of Lumryz in the second quarter of 2024.
As of June 30, there were more than 1,900 patients on Lumryz compared to more than 1,400 as of March 31.
Pediatric patients currently represent approximately 5% of all oxybate-treated narcolepsy patients. Hence, the label expansion of the drug for this population should boost sales.
In addition, a phase III double-blind, placebo-controlled, randomized withdrawal, multicenter study is evaluating the efficacy and safety of Lumryz in idiopathic hypersomnia (IH).&nbsp; Enrollment is open to patients who are currently being treated with a twice-nightly oxybate and those not taking oxybates. The study, which is expected to enroll approximately 150 adults diagnosed with IH, includes an open-label extension portion.
<h3>AVDL&#39;s Rank &amp; Other Stocks To Consider</h3>
Avadel carries a Zacks Rank #3 (Hold) at present.&nbsp; Some other top-ranked stocks in the drug/biotech sector are Catalyst Pharmaceuticals CPRX, ANI Pharmaceuticals ANIP and
<a href="https://www.zacks.com/stock/news/2353213/avadel-obtains-fda-nod-for-label-expansion-of-narcolepsy-drug-lumryz?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2353213">To read this article on Zacks.com click here.</a>

Biotech

Small Cap

General

ALNY

ANIP

Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz

Catalyst Pharmaceuticals, Inc.&nbsp;("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE&#xAE; (amifampridine) Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome ("LEMS") in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.
"We are pleased that our partner, DyDo, has secured regulatory approval for FIRDAPSE in Japan. This represents a meaningful milestone, bringing renewed hope to patients and further affirming FIRDAPSE's proven effectiveness in the treatment of LEMS," said Richard J. Daly, Catalyst's President and Chief Executive Officer. "This achievement underscores our unwavering commitment to advancing patient care. We appreciate the collaborative efforts of our partner in securing this approval, and we remain focused on expanding our innovative rare disease product portfolio beyond the U.S. to make a meaningful impact on patients' lives worldwide."
FIRDAPSE (amifampridine) is a leading therapy indicated in the United States for the treatment of LEMS in adults and pediatric patients six years of age and older. LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. About 50% of people with LEMS have underlying cancer, as LEMS is observed in approximately 3% of small-cell lung cancer patients. FIRDAPSE is the only U.S. FDA-approved, evidence-based treatment for LEMS. As a cornerstone of Catalyst's commitment to serving those with rare diseases, FIRDAPSE is supported in the U.S. by a comprehensive patient support program to help ensure accessibility and assistance for eligible U.S. patients.

Government

Regulations

Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")

As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</h3>
<ul>
<li>On Aug. 14, Cardinal Health posted better-than-expected quarterly results. &#8220;Fiscal 2024 marked a year of strong operational execution and record financial results, delivered in tandem with key strategic progress in the portfolio,&#8221; said Jason Hollar, CEO of Cardinal Health. The company's stock gained around 9% over the past month and has a <a href="https://www.benzinga.com/quote/CAH">52-week high of $116.04</a>.</li>
<li>RSI Value: 72.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CAH Price Action: Shares of Cardinal Health gained 1.9% to close at $102.58 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Catalyst Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>)</h3>
<ul>
<li>On Aug. 7, Catalyst Pharmaceuticals reported better-than-expected second-quarter financial results. &#8220;Since the onset of this year, we have advanced with continued momentum, propelled by the strong performance of our established product portfolio and the successful U.S. commercial launch of AGAMREE. Our accomplishments have significantly strengthened our financial position, aligning with our revenue guidance for the year, and we believe that we are on track to achieve the upper end of our previously provided total revenue forecast,&#8221; stated Richard J. Daly, President and CEO of Catalyst. The company's stock gained around 19% over the past five days and <a href="https://www.benzinga.com/quote/CPRX">has a 52-week high</a> of $19.86.</li>
<li>RSI Value: 73.73</li>
<li>CPRX Price Action: Shares of Catalyst Pharmaceuticals gained 1.5% to close at $19.59 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Verona Pharma PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>)</h3>
<ul>
<li>On Aug. 8, Verona Pharma posted a narrower-than-expected quarterly loss. &#8220;We are very pleased today to announce that Ohtuvayre (ensifentrine) is now available in the US for the maintenance treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;) in adults,&#8221; said David Zaccardelli, Pharm. D., President and Chief Executive Officer. The company's stock gained around 26% over the past five days and has a <a href="https://www.benzinga.com/quote/VRNA">52-week high</a> of $28.26.</li>
<li>RSI Value: 71.22</li>
<li>VRNA Price Action: Shares of Verona Pharma gained 8.3% to close at $26.73 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40357992/brinker-international-cisco-and-3-stocks-to-watch-heading-into-wednesday">Brinker International, Cisco And 3 Stocks To Watch Heading Into Wednesday</a></li>
</ul>

Top 3 Health Care Stocks That May Crash In August

5 analysts have expressed a variety of opinions on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Catalyst Pharmaceuticals and provided 12-month price targets. The average target is $29.2, accompanied by a high estimate of $31.00 and a low estimate of $26.00. Witnessing a positive shift, the current average has risen by 9.77% from the previous average price target of $26.60.
<img src="https://www.benzinga.com/files/images/story/2024/1723467649_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Catalyst Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Samantha Semenkow</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Catalyst Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Catalyst Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Catalyst Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Catalyst Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Catalyst Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Catalyst Pharmaceuticals Better</h2>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Catalyst Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 23.23% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Catalyst Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 33.24%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Catalyst Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 6.97%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Catalyst Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.03% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Catalyst Pharmaceuticals

HC Wainwright &amp; Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $26 to $30.

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $30

Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $27 to $31.

Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31

Truist Securities analyst Joon Lee maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $25 to $30.

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $30

Catalyst Pharmaceuticals, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cprx#NASDAQ">CPRX</a>) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the Zacks Consensus Estimate of 42 cents. The company reported adjusted earnings of 53 cents in the year-ago quarter.
Total revenues, the majority of which comprised product revenues, amounted to $122.7 million in the reported quarter, representing growth of 23% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $111.6 million.
Catalyst&#39;s top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and Fycompa (perampanel) CIII. Revenues generated from the sale of the newly launched Agamree (vamorolone) also contributed to the top line.
The stock is gaining in the pre-market hours on Aug 8 as the investors are impressed by the better-than-expected second-quarter results. Year to date, shares of CPRX have lost 3.5% compared with the&nbsp;industry&#39;s 4.6% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/3b/73700.jpg?v=1117266918" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h3>Quarter in Detail</h3>
Firdapse generated sales worth $77.4 million in the second quarter, up 19.2% year over year. The reported figure beat the Zacks Consensus Estimate of $72.5 million and our estimate of $72.9 million, driven by the organic sales growth of Firdapse. The drug has been witnessing strong demand and increasing prescription rates from LEMS patients, as well as continued diagnosis of new LEMS patients.
Catalyst also started recording sales of its newest epilepsy asset, Fycompa, from the first quarter of 2023. In 2023, CPRX acquired the&nbsp;U.S.&nbsp;rights for Fycompa (perampanel) CIII from Eisai Co., Ltd. This acquisition diversified the company&#39;s portfolio by adding a commercial-stage epilepsy asset.
Fycompa generated robust net product revenues of&nbsp;$36.5&nbsp;million in second-quarter 2024, which beat the Zacks Consensus Estimate of $33.2 million as well as our model estimate of $33.6 million. Fycompa sales recorded year-over-year growth of 5.7%.
In the third quarter of 2023, CPRX acquired exclusive rights to manufacture and supply Agamree from Santhera Pharmaceuticals through a licensing agreement.
In late 2023, the FDA approved Agamree for treating Duchenne Muscular Dystrophy in patients aged two years and older, which gave Catalyst a third approved product. The drug was commercially launched in the United States in the middle of March 2024.
In the first full quarter of commercialization since launch, Agamree generated revenues worth $8.7 million, which beat the Zacks Consensus Estimate of $6 million and our estimate of $5.2 million. Per Catalyst, early indicators for the drug&#39;s U.S. launch suggest strong demand that exceeds initial expectations.
Research and development (R&amp;D) expenses were $3 million in the reported quarter, down 25% year over year.
Selling, general and administrative (SG&amp;A) expenses totaled $40.7 million, up 43% from $28.4 million reported in the year-ago quarter. This uptick in costs is primarily due to the launch of Agamree and the cumulative commercial and marketing activities to support three commercial products compared with two in 2023.
As of Jun 30, 2024, Catalyst had cash, cash equivalents and investments worth $375.7 million compared with $310.4 million as of Mar 31, 2024.
<h3>2024 Financial Guidance Updated</h3>
Catalyst continues to expect total revenues in the range of&nbsp;$455-$475 million for the full year, boosted by the continued growth of Firdapse, Fycompa and additional net product revenues from Agamree. The company believes that the total revenue figure for 2024 will lie toward the high end of its projected range.
For 2024, the company continues to expect Firdapse revenues between $295 million and $310 million and Fycompa revenues in the $130-$135 million band. Catalyst, however, increased its revenue guidance for Agamree in the range of $35-$40 million from the previously guided range of $25-$30 million, based on the promising demand trend and an encouraging payer landscape.
<div class="chart_embed">
<h3>Catalyst Pharmaceuticals, Inc. Price and Consensus</h3>
<img alt="Catalyst Pharmaceuticals, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/59/1723118796.png" style="height:310px; width:600px" title="" />
Catalyst Pharmaceuticals, Inc. price-consensus-chart | Catalyst Pharmaceuticals, Inc. Quote
</div>
<h3>Regulatory Update</h3>
In May 2024, Catalyst announced the FDA approval of its supplemental new drug application to increase the maximum daily dose of Firdapse for adults and pediatric patients over 45 kg from 80 mg to 100 mg for treating LEMS.
Per CPRX, this higher dose provides healthcare providers and patients with more flexibility in managing LEMS treatment regimens. This development is expected to spike sales of the drug in the upcoming quarters.
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Catalyst currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Annovis Bio,&nbsp;Anixa Biosciences&nbsp;and&nbsp;Akero Therapeutics, each carrying a Zacks Rank #2 (Buy) at present.
In the past 60 days, the Zacks Consensus Estimate for Annovis&#39; 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has narrowed from $1.95 to $1.91. Year to date, shares of ANVS have plunged 57.1%.
ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.
In the past 60 days, the Zacks Consensus Estimate for Anixa Biosciences&#39; 2024 loss per share has narrowed from 44 cents to 43 cents. During the same time frame, the estimate for Anixa Biosciences&#39; 2025 loss per share has remained constant at 45 cents. Year to date, shares of ANIX have lost 22.2%.
ANIX beat estimates in three of the trailing four quarters and missed the mark once, delivering an average earnings surprise of 2.27%.&nbsp;
In the past 60 days, estimates for Akero Therapeutics&#39; 2024 loss per share have narrowed from $3.87 to $3.82. During the same period, loss per share estimates for 2025 have remained constant at $4.29. Year to date, shares of AKRO have gained 1.4%.
Akero&#39;s earnings beat estimates in one of the trailing four quarters, missed twice and matched once, delivering an average negative surprise of 5.10%.
<a href="https://www.zacks.com/stock/news/2319318/catalyst-cprx-rises-as-q2-earnings-revenues-beat-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-2319318">To read this article on Zacks.com click here.</a>

Catalyst Rises as Q2 Earnings & Revenues Beat Estimates

WIIM

Catalyst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Catalyst Pharmaceuticals Reaffirms 2024 Total Revenue Guidance Of $455M – $475M, Expecting Results In Upper Range Of Range; Est $462.433M

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.26 by 115.38 percent. This is a 5.66 percent increase over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $122.710 million which beat the analyst consensus estimate of $111.866 million by 9.69 percent. This is a 23.23 percent increase over sales of $99.582 million the same period last year.

Catalyst Pharmaceuticals Q2 2024 Adj. EPS $0.56 Beats $0.26 Estimate, Sales $122.710M Beat $111.866M Estimate

As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Verona Pharma PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>)</h3>
<ul>
<li>Verona Pharma will report its financial results for the second quarter on Thursday, Aug. 8. The company's stock gained around 46% over the past month and has a <a href="https://www.benzinga.com/quote/VRNA">52-week high of</a> $23.72.</li>
<li>RSI Value: 71.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VRNA Price Action: Shares of Verona Pharma fell 0.5% to close at $22.61 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Catalyst Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>)</h3>
<ul>
<li>On July 24, Catalyst Pharmaceuticals entered into an exclusive license, supply and commercialization agreement with Kye Pharmaceuticals for AGAMREE&#xAE; in Canada. &#8220;We are pleased to enter into this agreement with Kye Pharmaceuticals for AGAMREE, marking a pivotal milestone in our strategic initiative to expand the product&#8217;s footprint in North America. This collaboration leverages our combined expertise, fortifies our alliance by licensing our second therapeutic rare disease product for Canada, and demonstrates our sustained commitment to patient care,&#8221; stated Richard J. Daly, CEO and President of Catalyst. The company's stock gained around 11% over the past month and <a href="https://www.benzinga.com/quote/CPRX">has a 52-week high</a> of $17.99.</li>
<li>RSI Value: 70.99</li>
<li>CPRX Price Action: Shares of Catalyst Pharmaceuticals fell 0.6% to close at $17.48 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Viridian Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>)</h3>
<ul>
<li>On July 29, Wedbush maintained an Outperform rating on the stock and reiterated its price target of $42. The company's stock gained around 31% over the past month and has a <a href="https://www.benzinga.com/quote/VRDN">52-week high</a> of $24.18.</li>
<li>RSI Value: 73.86</li>
<li>VRDN Price Action: Shares of Viridian Therapeutics gained 3.8% to close at $17.29 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40009447/roblox-morgan-stanley-and-2-other-stocks-insiders-are-selling">Roblox, Morgan Stanley And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

VRDN

Top 3 Health Care Stocks You May Want To Dump This Quarter

Catalyst Pharmaceuticals Enters Exclusive License, Supply And Commercialization Agreement Granting Kye Pharmaceuticals Canadian Rights To AGAMREE For Duchenne Muscular Dystrophy

Reports Q3 revenue $128.7M, consensus $123.42M. "Our strong financial performance reflects our unwavering commitment to operational and commercial ...

Catalyst Pharmaceuticals reports Q3 non-GAAP EPS 57c, consensus 30c

Expect total revenues for the full year 2024 to be between $475 million and $485 million, which includes the $2.1 million milestone payment receive...

Catalyst Pharmaceuticals sees FY24 revenue $475M-$485M, consensus $473.67M

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – AppLovin (APP)&nbsp;up 28.6% ...

Closing Bell Movers: AppLoving up 29% after Q3 earnings beat

Citi analyst Samantha Semenkow maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of $31.00. Samantha...

Catalyst Pharma's Strong Performance and Growth Prospects Earn a Buy Rating

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Smaller Cap Biotechs Are In Season: How Are We Doing?

Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of $29.00. The...

Oppenheimer Keeps Their Buy Rating on Catalyst Pharma (CPRX)

Truist Financial analyst Joon Lee reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of $36.00. The c...

Truist Financial Sticks to Their Buy Rating for Catalyst Pharma (CPRX)

Truist raised the firm's price target on Catalyst Pharmaceuticals (CPRX) to $36 from $30 and keeps a Buy rating on the shares. The company's Q3 res...

Catalyst Pharmaceuticals price target raised to $36 from $30 at Truist

Stephens initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Overweight rating and $35 price target The firm is adding to its Biotechnolo...

Comments

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (CPRX) Opzioni

Catalyst Pharmaceuticals (NASDAQ:CPRX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO